



Outcomes	Serranator* (n=20)	POBA* (n=19)	P value
Mean recoil across all lesions <u>at 15min (</u> +/- SD)	6%	55%	p = 0.009
	(+/- 26)	(+/- 69)	
Recoil	Serranator* (n=20)	POBA* (n=19)	POBA/ Baumann** (n=30)
% of lesions with recoil defined as: 10% lumen compromise at 15 min	25%	63%	97%
	(5/20)	(12/19)	(29/30)
Clinically Relevant Recoil (CRR)	Serranator* (n=20)	POBA* (n=19)	
% of lesions with recoil (CRR is defined as 230%) lumen compromise at 15 min)	10%	53%	
	(2/20)	(10/19)	























Summary

- Dedicated devices need to address recoil and dissection for acute lumen gain may be considered as standard of care
- Device needs to be
 - Deliverable
 - Effective
 - Cost effective
- Serranator balloon may addresses most of these needs